Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris

Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus

(2019) Carolyn J. Kushner et al.   JAMA Dermatology

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reducing Ex Vivo Culture Improves the Anti-leukemic Activity of Chimeric Antigen Receptor (CAR)-T Cells

(2018) Saba Ghassemi et al.   Cancer Immunology Research

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

(2018) Frederick L Locke et al.   LANCET ONCOLOGY

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody–Activated Chimeric Antigen Receptor–Modified T Cells

(2017) Michael Schmueck-Henneresse et al.   JOURNAL OF IMMUNOLOGY

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial

(2017) Pascal Joly et al.   LANCET

Pemphigus

(2017) Michael Kasperkiewicz et al.   Nature Reviews Disease Primers

Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease

(2016) C. T. Ellebrecht et al.   SCIENCE

Memory T cell–driven differentiation of naive cells impairs adoptive immunotherapy

(2015) Christopher A. Klebanoff et al.   JOURNAL OF CLINICAL INVESTIGATION

Mucosal Pemphigus Vulgaris Anti-Dsg3 IgG Is Pathogenic to the Oral Mucosa of Humanized Dsg3 Mice

(2015) Donna A. Culton et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

A Rapid Method to Characterize Mouse IgG Antibodies and Isolate Native Antigen Binding IgG B Cell Hybridomas

(2015) Haolin Liu et al.   PLoS One

Tissue-based map of the human proteome

(2015) M. Uhlen et al.   SCIENCE

Remission Time after Rituximab Treatment for Autoimmune Bullous Disease: A Proposed Update Definition

(2015) Pilar Iranzo et al.   SKIN PHARMACOLOGY AND PHYSIOLOGY

Study of T helper 1 and T helper 2 responses in pemphigus vulgaris patients receiving interferon alpha 2a injections in addition to a standard protocol therapy: a randomized controlled trial

(2014) Mohammad A. El-Darouti et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Pathogenic IgG Antibodies against Desmoglein 3 in Pemphigus Vulgaris Are Regulated by HLA-DRB1*04:02–Restricted T Cells

(2014) Rüdiger Eming et al.   JOURNAL OF IMMUNOLOGY

Long-Term Remissions of Severe Pemphigus After Rituximab Therapy Are Associated with Prolonged Failure of Desmoglein B Cell Response

(2013) N. Colliou et al.   Science Translational Medicine

The Origin and Evolution of Variable Number Tandem Repeat of CLEC4M Gene in the Global Human Population

(2012) Hui Li et al.   PLoS One

Transgenic rescue of desmoglein 3 null mice with desmoglein 1 to develop a syngeneic mouse model for pemphigus vulgaris

(2011) Tsuyoshi Hata et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients

(2010) Enno Schmidt et al.   EXPERIMENTAL DERMATOLOGY

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates

(2008) Carolina Berger et al.   JOURNAL OF CLINICAL INVESTIGATION